Glucosamine+Chondroitin+MSM: instructions for use, description, reviews, application

Manufacturer: Ultimate Nutrition, Inc. (USA)
Active ingredients

Not indicated. See instructions

Pharmacological action

Not indicated. See instructions

Description of the pharmacological action of Glucosamine + Chondroitin + MSM
Composition Glucosamine+Chondroitin+MSM
Indications for use of the drug Glucosamine + Chondroitin + MSM
Release form of the drug Glucosamine + Chondroitin + MSM
Method of administration and dosage of the drug Glucosamine + Chondroitin + MSM
Storage conditions for the drug Glucosamine + Chondroitin + MSM
Shelf life of the drug Glucosamine + Chondroitin + MSM

Description of pharmacological action

• Promotes regeneration (restoration) of damaged cartilage tissue. • Has an anti-inflammatory effect, relieves pain and tension in the joints, increases their mobility, reduces swelling. • Participates in the formation and improves the trophism of connective tissue of articular surfaces, tendons, ligaments, synovial fluid, skin, bone tissue, nails, heart valves, blood vessels and mucous membranes of the digestive, respiratory and urinary tracts. • Has a beneficial effect on cartilage metabolism - enhancing anabolic and weakening catabolic processes. • Stimulates collagen synthesis. • Inhibits the activity of enzymes that destroy connective tissue, incl. cartilage. • Improves microcirculation of the vascular bed of periarticular tissues. • Stimulates the synthesis of hyaluronic acid, which provides lubrication necessary for the functioning of joints. • Participates in the processes of bone mineralization, regulating calcium balance and promoting ossification processes. • Has an antithrombotic heparin-like effect. • Chondroitin sulfate is also necessary for any pathological processes of connective tissue, not only cartilage, but also tendons, ligaments and, of course, skin. Therefore, not only sports doctors should have chondroitin sulfate in their arsenal, but also competent dermatologists and cosmetologists. Unfortunately, the latter very rarely turn to cosmetic products for oral administration. Chondroitin sulfate, like vitamins A, B, C, E, can be called enteral cosmetic preparations. • Promotes healing of fractures, wounds, erosions, ulcers. • Reduces the concentration of cholesterol in the blood, prevents the accumulation of atherosclerotic plaques on the walls of blood vessels, improves blood circulation. • Methylsulfonylmethane (organic sulfur, MSM) provides the molecular structure of protein, is part of many amino acids, and is involved in the synthesis of antioxidants, in particular glutathione. Sulfur is essential for joint tissues, where it is responsible for the stability of cartilage tissue, capsule and ligaments. MSM has a positive effect on joint pain, helps restore joint mobility, and also improves the permeability of cell walls, allowing fluid and substances dissolved in it to more easily penetrate cell membranes. This facilitates the removal of substances such as lactic acid and taxins from the cells, and the entry of nutrients and microelements into the cells. MSM prevents an increase in intracellular pressure, which relieves pain.

What happens to the body?

Many sports cannot do without microtraumas of tendons, joints and ligaments. Monotonous force or speed loads often cause joint damage or aggravate the pathological process. Especially at risk are those who engage in football, weightlifting, boxing, tennis, running, contact sports, ski jumping and other similar activities. Systematic loads with a sharp increase in working weight, incorrect execution technique, lack of rest between workouts - all this threatens to increase pressure on the joints.

For example, when lifting a barbell, the elbow joints suffer, as a result of squats with heavy weights, the knee joints, and when exercising on weight machines, the vertebrae suffer.

Why do joints stop functioning normally?

The cartilage tissue, which softens the friction of the articular surfaces against each other, wears out and wears out, and less and less joint fluid is produced. The joints dry out and become inflamed, they no longer play the role of a shock absorber during mobility - this is where destructive changes begin, which over time develop into osteoarthritis or other diseases. Later this can lead to ossification and complete disability. Enriching sports nutrition with glucosamine and chondroitin can prevent joint degradation.

Symptoms of joint damage:

Pain. It may go away after rest and appear again.
Edema.
Limitation of mobility.
Crunching or clicking noises while driving.
When you press on a joint, pain occurs.

Unfortunately, all of the above affects both professional athletes and amateurs, or those who simply want to lose weight by working out in the gym. To prevent joint diseases, it is important to warm up before training, allocate enough time for recovery after physical activity, and also use dietary supplements - glucosamine and chondroitin

. And the main thing is to follow the execution technique and not rush.

Indications for use

• Inflammatory and metabolic diseases and injuries of the osteoarticular system: osteoporosis, osteochondrosis, fractures, ankylosing spondylitis, tendovaginitis, bursitis, arthritis, arthrosis, gout, rheumatoid polyarthritis. • Recovery period after injuries, bone fractures, and “jumper’s knee” in athletes. • Wound healing effect (postoperative conditions, trophic ulcers). • Increased brittleness of nails, hair loss. • Cardiovascular diseases (varicose veins, heart defects, atherosclerosis). • In cosmetology to restore skin texture, improve tone, smooth and reduce the number of wrinkles, skin rejuvenation, treatment of hyperpigmentation.

How to take glucosamine and chondroitin?

All chondroprotectors have a cumulative effect

– it appears after about 4-5 weeks of regular use.
It is advisable to take with meals. Chondroprotector "Artracam" is a domestic drug, one sachet of which contains the daily dose of glucosamine sulfate.
According to research, it is in this form that it shows the greatest bioavailability and is absorbed faster by the body. It shows particular effectiveness in the early stages, when changes are least pronounced.

To prepare the solution, 1 sachet is enough - the powder must be dissolved in 200 ml of water. Artrakam

can be combined with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids.

Before taking, pay attention to the list of contraindications for glucosamine and chondroitin!

Course – 6 weeks.

You can continue taking it after a two-month break - in this case, you should check with your doctor for more details on how to take glucosamine and chondroitin specifically for you.

Glucosamine and chondroitin are an important part of sports nutrition.

They are necessary to maintain the functionality of joints and the entire body.

Healthy and mobile joints!

Best before date

24 months

Vitamins with similar effects

Impulsen (Capsule)
Hyssop officinalis (Briquet)
Source of Life "Animal Parade" Assorted (Chewable tablets)
Yoshi Vitamin Jelly Drink (vitamin complex) (Liquid for oral administration)
Marine calcium for children with iron (Oral tablets)
Marine calcium for children with iodine (Oral tablets)
Pankragen (Capsule)
Pantohematogen "Altamar™-3" (Capsule)
Pantohematogen "Altamar™-4" (Oral tablets)

The description of the vitamin Glucosamine + Chondroitin + MSM is intended for informational purposes only. Before starting to use any drug, it is recommended to consult a doctor and read the instructions for use. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the project does not replace consultation with a specialist and cannot be a guarantee of the positive effect of the drug you use. The opinions of EUROLAB portal users may not coincide with the opinions of the site Administration.

Are you interested in vitamin Glucosamine+Chondroitin+MSM? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.

Attention! The information presented in the vitamins and dietary supplements section is intended for informational purposes and should not be a basis for self-medication. Some of the drugs have a number of contraindications. Patients need to consult a specialist!

If you are interested in any other vitamins, vitamin-mineral complexes or dietary supplements, their descriptions and instructions for use, their analogues, information about the composition and form of release, indications for use and side effects, methods of use, dosages and contraindications, notes about the prescription of the drug for children, newborns and pregnant women, price and consumer reviews, or you have any other questions and suggestions - write to us, we will definitely try to help you.

How to integrate glucosamine and chondroitin into sports nutrition?

Glucosamine and chondroitin for joints can be obtained from food.

For example, from mussels, lobsters, cartilage, animal bones, but there is a minus - in products their volume is minimal, and in plants they are practically absent. It is also important to remember about heat treatment - some of the beneficial substances are also lost because of it. To get the required daily intake, you will have to eat a lot of cartilage or chitinous shell of crustaceans - for example, crayfish shells.

The most optimal source of glucosamine and chondroitin are dietary supplements

. Nutritional supplements help you get the required daily dose of these substances at one time - and there is no need to overuse jellied meats and meat broths! Bioadditives include sachets or glucosamine and chondroitin for athletes in the form of tablets.

Do Chondroitin or Glucosamine Have Side Effects?

Glucosamine in joint supplements is naturally occurring and is extracted from insect shells or shellfish shells (shrimp, lobster, etc.). It is sometimes obtained from wheat or corn. Due to this, chondroitin is considered a completely safe substance and only rarely causes:

gastrointestinal problems (nausea, bloating, diarrhea or constipation);

drowsiness;

headache;

swelling of the eyelids;

slight hair loss;

allergic reactions (swelling, heart rhythm disturbances).

Taking chondroitin with glucosamine is not allowed if:

seafood allergies;

thrombophlebitis and other blood clotting disorders;

asthma.

Complex drugs

Glucosamine or chondroitin: which is better? Preferred are complex preparations that contain both active components:

Artra;
Teraflex;
Teraflex Advance (also contains ibuprofen);
Doppelhertz Active Glucosamine + Chondroitin;
Kondronov;
Inoltra (additionally includes vitamins E and C, manganese, omega-3 fatty acids);
Glucosamine-Chondroitin Plus;
Glucosamine-chondroitin complex.

The listed medications differ in the content of active ingredients, place of production, and price. The choice of a specific complex depends on the required dosage and the preferred cost level. Before visiting a pharmacy, it is better to consult a doctor.

Side effects and contraindications

Tests have shown the absolute safety of glucosamine and chondroitin. If the daily norm is significantly exceeded (over 3 thousand mg), intestinal upset and headache may occur, and effectiveness may decrease. If the dosage is systematically exceeded, there is a risk of diabetes mellitus.

There are no special contraindications to taking chondoprotectors of this type. No serious adverse reactions were detected. They can be used without a doctor’s advice to strengthen the musculoskeletal system. As part of a dietary supplement, they saturate the body tissues much faster and in higher concentrations than in food products.

Who needs it?

Thus, glucosamine and chondroitin are needed by the body, but who needs them especially? Every person needs chondoprotectors, but some categories require a constant supply. In such cases, the menu will not be able to provide a full level. Preparations based on both elements will help saturate the body. They are shown:

after fractures and joint injuries;
for osteochondrosis, arthrosis, osteoarthritis, arthritis and other joint pathologies,
people experiencing increased physical activity;
athletes.
with age-related changes in the musculoskeletal system;

It is easier to prevent a disease than to treat it for a long time. Therefore, all people, regardless of age and stress experienced, are recommended to monitor the health of their joints. Numerous clinical studies have proven that taking chondoprotective agents helps reduce pain and swelling and restore cartilage tissue.

Release forms and recommendations

You can find chondroprotectors in several forms on the shelves of pharmacies and specialty stores. These can be capsules, tablets or powder - for systemic use. In addition, there are preparations for local action - ointments and creams. Depending on the severity of the injury or joint wear, choose between systemic and local action.

Choosing products at a pharmacy or buying them in sports nutrition stores is a matter of convenience, since not every city has points of sale of supplements for athletes. Both in the pharmacy and in the sports nutrition store, the quality level of drugs is controlled at the state level. Therefore, the risk of buying a jar or tube containing a counterfeit from a reputable chain is minimal.

For serious injuries and pain in the joint while walking, it is not recommended to opt for ointments and creams, as they provide minimal therapeutic effect. If we talk about the difference between capsules and tablets, it must be said that capsules have an advantage because the substances from them are absorbed faster, regardless of food intake.

The dosage is calculated based on the information on the packaging. It is important to remember that for preventive purposes it is less than for the treatment of pathologies of the musculoskeletal system.

Specialists

Blair Yasso1, Yinghe Li2, Asafov Alexander3; Melnikova N.B.4, Mukhina I.V.5

1 MB Research Laboratories, 1765 Wentz Road, Spinnerstown, PA 18968, USA, Blair Yasso, BS, Study Director;

2 Alliance Pharma, Inc., 17 Lee Blvd, Malvern, PA 19355, USA, Yinghe Li, Bioanalytical Principal Investigator;

3 Foura Pacific Pte Ltd, (Singapore), 35 Selegie Road #10-05, Parklane Shopping Mall, Singapore 188307, Asafov Alexander, R&D, CEO;

4 Department of Pharmaceutical Chemistry of the State Budgetary Educational Institution of Higher Professional Education Nizhny Novgorod State Medical Academy of the Ministry of Health of Russia (head of the department - Professor, Doctor of Chemical Sciences Melnikova N.B., Nizhny Novgorod, Rodionova St., 293)

5 Central Research Laboratory of the State Budgetary Educational Institution of Higher Professional Education Nizhny Novgorod State Medical Academy of the Ministry of Health of Russia (Head of the Central Research Laboratory - Professor, Doctor of Biological Sciences Mukhina I.V., Nizhny Novgorod, Gagarin Ave., 70)

Key
words
: relative bioavailability, glucosamine sulfate, transdermal glucosamine complex, micellar transdermal delivery system.

SUMMARY

A comparison was made of the relative bioavailability and intensity of penetration of glucosamine sulfate during oral, injection and local administration of the drug Chondroxide® Maximum in the form of a cream containing a micellar system for transdermal delivery of glucosamine in an experiment on Sprague-Dawley rats. Based on the analysis of the pharmacokinetic profiles of glucosamine in the blood plasma of rats, it was found that when administered daily 3 times a day for a week, Chondroxide® Maximum cream at a dose of 400 mg/kg and a single injection of a 4% solution of Glucosamine sulfate at a dose of 400 mg/kg, the relative bioavailability was 61.6%. The average rate of penetration of glucosamine into the blood plasma through the skin of rats in 4 hours was calculated, equal to 26.9 μg/cm2∙h, and the proportion of penetration of glucosamine from the cream through the skin into the blood plasma of the animal with a single administration in 4 hours, which amounted to 4.12% .

A comparative analysis of literary and experimental data, as well as calculations based on them, allowed us to conclude that, during treatment in accordance with the instructions for the drug Chondroxide® Maximum, the estimated average concentration of glucosamine in the synovial fluid of an inflamed joint can be (0.7– 1.5) µg/ml, which is 10-75 times higher than the concentration of endogenous glucosamine in the synovial fluid of a human joint (0.02-0.07) µg/ml. This value is comparable to the level achieved by injectable forms of glucosamine and is up to 2 times higher than the level achieved by oral forms of glucosamine.

INTRODUCTION

Glucosamine (2-amino-2-deoxy-D-glucose) has reliably proven itself as a chondroprotector in the prevention and treatment of metabolic disorders of bone and connective tissue, in particular in collagen and cartilage matrices. According to the review by R.D. Altman glucosamine as a drug demonstrated symptomatic and osteoarthritis-modifying effects. Glucosamine in this case is a specific substrate and stimulator of the synthesis of endogenous glycosaminoglycans (hyaluronic acid, chondroitin sulfate A and C, dermatan sulfate, keratan sulfate, heparin and heparan sulfate) and, accordingly, proteoglycans, which, along with hyaluronic acid, are one of the main components - building elements of the extracellular matrix connective tissue. The lack of endogenous glucosamine causes inflammatory and degenerative changes, so the development and course of such diseases is greatly influenced by the concentration of glucosamine in the synovial fluid, which can be replenished by introducing glucosamine into the blood plasma using one of the routes discussed here.

Modern research has revealed new additional positive effects from the administration of glucosamine, including normalization of enzyme activity due to the antioxidant protection of superoxide dismutase and catalase, inhibition of the formation of malondialdehyde and diene conjugates - intermediate stages of collagen oxidation, a positive effect on the activity of NO synthase, which generates nitrogen monoxide , with the participation of which glucosamine is synthesized, replenishing the deficiency of sulfate ions necessary for the synthesis of specific glycosaminoglycans.

Glucosamine preparations are widely represented by oral, injection and topical dosage forms containing glucosamine hydrochloride or glucosamine sulfate, suggesting a single dose of 100 to 1500 mg. The reason limiting the use of oral glucosamine preparations in practice is the need to use high concentrations of glucosamine during long-term use to ensure the necessary bioavailability, which can lead to a pro-antioxidant effect. Existing external dosage forms (cream, ointment, emulsion, gel) containing glucosamine do not have an effective mechanism for its transfer to the synovial membrane surrounding the affected area. Therefore, despite the high potential effectiveness of glucosamine, the therapeutic effect of classical local remedies is much inferior to the oral form. Injectable drugs, with their maximum bioavailability, are limited by the method of administration, which is not acceptable for all patients, as well as the need for their use with the participation of professional medical personnel.

One of the ways to improve the bioavailability of glucosamine from external preparations is to introduce a transdermal delivery system for this compound into the dosage form. A representative of such drugs with improved bioavailability is the drug Chondroxide® Maximum, which contains a micellar transdermal glucosamine complex (THC) as a system for the effective delivery of glucosamine into the blood and joint tissues. The achievement of high penetration of THC through the skin is due to the size of micelles of 20-80 nm and the participation in the formation of the micellar system of triglycerides, which enhance the lipophilicity of dispersed phase particles in a direct cream emulsion.

Unfortunately, to date, there have been no pharmacokinetic studies to identify the benefits of using such a transdermal complex and compare its effect with oral and injectable forms, which has hampered the large-scale introduction of this drug into practice.

The purpose of the study

was a comparative experimental study of the relative bioavailability and intensity of penetration of glucosamine sulfate upon its oral and injection administration and local administration of the drug Chondroxide® Maximum THC in an experiment on Sprague-Dawley rats, as well as prediction of the glucosamine content in the synovial fluid of an inflamed human joint.

MATERIALS AND METHODS

Experimental studies were conducted at MB Research Laboratories Spinnerstown, PA (USA) with the assistance of the analytical laboratory Alliance Pharma, Inc., Malvern, PA (USA) in accordance with the Regulations and principles of the current GLP (Good Laboratory Practices) regulations of the Environmental Protection Agency (EPA), 40 CFR Part 160 and 792, Food and Drug Administration (FDA), 21 CFR Part 58, and OECD.

The comparative bioavailability of glucosamine for oral, injection and local administration was studied experimentally using a 4% aqueous solution of Glucosamine sulfate potassium chloride (40 mg of dry powder Glucosamine sulfate/ml) for oral administration and intramuscular administration, distilled water and sterile water for injection were used as the solvent, respectively. . To study external use, the drug Chondroxide® Maximum (Licht Far East (S) Pte. Ltd., Singapore) was applied in the form of a cream containing a system for transdermal delivery of glucosamine in the form of micelles. The composition of the cream (per 100 g) includes: glucosamine sulfate, potassium chloride 8.0 g, excipients, in particular, dimethyl sulfoxide - 1.0 g, ascorbic acid - 0.1 g and formative ingredients. Sprague - Dawley rats weighing 250±25 g ( n =45, each group is 9 - the minimum sufficient number required to be able to take 3 analyzes for each time point (0 hours, 0.5 h, 1 h, 2 h, 4 h, 6 h) and obtain statistically significant data ). At the end of the experiment, the animals were euthanized in a CO2 chamber.

The dose of the study drug Chondroxide® Maximum in the form of a cream for the active substance was 400 mg/kg or for the dosage form 5 g/kg (102 mg/rat). The drug was used externally in the form of a cutaneous application and light rubbing into the back area, from the shoulders to the pelvic bone and down from the back to the abdomen on both sides of the animal, with a total surface of 39 cm2. The application site was left uncovered.

The dose of the studied 4% solution of Glucosamine sulfate potassium chloride for oral administration according to the active substance was 400 mg/kg (88.8 mg/rat). A 4% solution of glucosamine sulfate was administered orally in a volume of 10 ml/kg.

The dose of the studied 4% injection solution was 400, 100 and 25 mg/kg (102.4, 25.9 and 6.2 mg/rat, respectively). The drug was administered intramuscularly in volumes of 10, 2.5 and 0.625 ml/kg of a 4% glucosamine sulfate solution, respectively.

Sample collection and plasma preparation for analysis were carried out according to the following scheme: 0.5 ml of whole blood was collected into tubes containing EDTA as an anticoagulant using direct venipuncture of the rat tail. Blood samples were centrifuged to separate the plasma, which was then divided into two equal parts and placed in two pre-labeled polypropylene cryogenic tubes with screw caps. All collected plasma samples were stored at -70±50C until dispatched via overnight courier (on dry ice) to the Alliance Pharma, Inc. laboratory. (Malvern, PA, USA) to perform the analysis. Analysis of animal blood plasma samples for glucosamine content was carried out using liquid chromatography-tandem mass spectrometry (LC-MS/MS), taking into account the principles described in detail in the article by Liang Zh. et al.. A compatible Sciex API 4000 QTrap mass spectrometer (USA) was used as a detector on a Shimadzu Prominence LC liquid chromatograph (Japan). Chromatograms were analyzed using the Analyst 1.4.2 program. D-Glucosamine Hydrochloride (Toronto Research Chemicals. Inc., Lot number 13-XJZ-183-1, purity 98%) was used as a calibration standard, D-Glucosamine-l,2-IJC2 Hydrochloride (10 μg/ml) was used as an internal standard. , Toronto Research Chemicals, Inc., Lot number 6-SXG-29-1, purity 98%). To construct a calibration graph for glucosamine, a regression method was used, and the lower level for determining the concentration of glucosamine in blood plasma for the developed method was 0.4 μg/ml.

The main pharmacokinetic characteristics were determined from the pharmacokinetic curves: Cmax

– maximum concentration of the drug in the blood;
C4 hours – the average concentration of the drug in the blood during the first 4 hours; tmax
– time to reach maximum concentration;
the
area under the concentration-time kinetic curve . Only AUCt was used to calculate bioavailability.

To assess the bioequivalence of the drug Chondroxide® Maximum in the form of a cream with the active ingredient Glucosamine sulfate, potassium chloride, in comparison with a 4% solution for oral use and a 4% solution for injection of Glucosamine sulfate, a statistical analysis of the obtained pharmacokinetic data (mean value, standard deviation, accuracy) was carried out. using the Watson LIMS™ software for bioanalytical laboratories and in accordance with the Guidelines for Preclinical Drug Studies.

RESEARCH RESULTS

At the first stage, the pharmacokinetic profile of glucosamine in the blood plasma of rats was studied with a single local administration of Chondroxide® Maximum cream (hereinafter referred to as “cream”) on the back area in the amount of 400 mg/kg (Table 1).

A comparison of the injection method of administration with the local one was carried out at three dose levels - 400 mg/kg (102.0 mg/rat), 100 mg/kg (25.9 mg/rat), 25 mg/kg (6.2 mg/rat) , reflecting the range in which the desired effect of glucosamine is realized in rats of a given species without signs of side effects. From the data in Figure 1(B) it is clear that in this dose range the linearity of pharmacokinetics is maintained. The maximum topical Cmax of 7.31 μg/ml is closest to the Cmax of 13.05 mg/ml determined from the pharmacokinetic curve for intramuscular administration at a dose of 25 mg/kg (6.2 mg/rat); AUCt values are 7.35 μg∙h/ml and 10.8 μg∙h/ml, respectively (Table 1).

A comparison of oral (400 mg/kg), intramuscular (25 mg/kg) and local (400 mg/kg) administration is shown in Table 1. From the data in Table 1 it can be seen that the Cmax of glucosamine in blood plasma after intramuscular (IM) administration was achieved after 0.5 hours, with local administration after 1 hour and with oral administration - after 1.5 hours.

Taking into account the above facts, to calculate the relative bioavailability of a cream with a dose of 102.0 mg/rat with a single administration, data on intramuscular administration of a 4% aqueous solution of glucosamine with a dose of 6.2 mg/rat were used.

A	B
IN

Figure 1. Plasma concentrations of glucosamine in Sprague - Dawley following different routes of administration. The ordinate is the concentration of glucosamine in µg/ml,

x axis – time of taking a blood sample

Table 1.

Pharmacokinetic parameters of glucosamine in the blood plasma of rats after a single dose

Location of curves, Fig. 1 (A B C)	A drug	Dose per rat according to dosage form, mg	Pharmacokinetic parameters
Location of curves, Fig. 1 (A B C)	A drug	Dose per rat according to dosage form, mg	Cmax µg/ml	C4 hours, mcg/ml	AUCt µg∙h/ml	tmax, h
1(A), 1(B)	Cream Chondroxide® Maximum (back)	102,0	7,31	1,84	7,35	1,0
1(B)	4% solution for oral use	88,8	11,7	4,93	19,7	1,5
1(B)	4% solution for injection (10 ml)	102,4	290,7	62,6	250,4	0,5
1(B), 1(C)	4% solution for injection (0.625 ml)	6,2	13,05	2,7	10,8	0,5

To select a criterion for comparative assessment of local administration in relation to other methods, an approximate calculation of the mass of glucosamine (GA) in rat plasma after a single administration (GGA, mg) was performed using the ratio of AUCtop to AUCx, and the mass of glucosamine in one dose for a certain method of administration of mGA (x):

SGA, mg = (AUCtop/ AUCx)* mGA(x),

where AUCx represents the values:

AUCin,max – AUC upon injection with a maximum dose of 102 mg per 1 rat;

AUCin,min – AUC upon injection with a dose of 6.2 mg per 1 rat;

AUCperos - AUC when administered orally with a dose of 88.8 mg per 1 rat.

table 2

Comparative characteristics of administration methods

Introduction	Comparison	AUCtop/ AUCх	SGA, mg
Locally 400 mg/kg (102 mg)	Injection 400 mg/kg mHA =102 mg	7,35/250,4	3,0
Locally 400 mg/kg (102 mg)	Injection 25 mg/kg mHA =6.2 mg	7,35/10,8	4,2
Locally 400 mg/kg (102 mg)	Oral 400 mg/kg mGA =88.8 mg	7,35/19,7	33,1

From the data in Table 2 it follows, for example, that a single application of a cream weighing 1.28 g (dose of glucosamine 102 mg) to a rat corresponds to a single injection of a 4% glucosamine solution in an amount of 4.2 mg.

CALCULATION OF COMPARATIVE BIOAVAILABILITY THROUGH HUMAN SKIN

The penetration of glucosamine from the cream through skin with an area of 39 cm2 into the blood plasma was assessed through the fraction α, % and the specific penetration rate υpr (specific diffusion)

The penetration fraction of glucosamine α (%) of a cream of mass m with a single local injection through the skin into the plasma in 4 hours was equal to:

α, % = (GAS in plasma, mg/ m, mg)*100 = 4.2/102 *100 = 4.12%,

and the specific penetration speed is υpr. glucosamine corresponded to 26.9 μg/cm2/h:

υpr = (SGA (6.2 mg) in plasma, μg/Skin, cm2)/ 4 h = (4200 μg/39 cm2)/4 h = 26.9 μg/cm2/h

The value α,% can be considered as the bioavailability of glucosamine 4 hours after applying the cream.

To predict the penetration of β in vivo glucosamine from the drug Chondroxide® Maximum into human skin, we used the following equation obtained by the authors of the article:

β invivohuman = K′eff * υinvivorat,

where K′eff = υinvitrohuman/υinvitrorat ≈ 0.3-0.5, determined in an experiment in a diffusion chamber using the dialysis method; υinvivorat = 26.9 μg/cm2/h.

In accordance with the above dependence, the specific rate of penetration (diffusion) of glucosamine into the blood plasma when applying the drug Chondroxide® Maximum to human skin was the value β invivohuman = (8.1-13.5) μg/cm2/h.

PREDICTION OF GLUCOSAMINE CONCENTRATION IN SYNOVIAL FLUID

The approximate estimate we obtained for the specific rate of transfer of glucosamine from the cream into the blood plasma of a rat in vivo, equal to 26.9 μg/cm2/h, is comparable to the value of the rate of transdermal transfer from a glucosamine solution to the skin in in vitro experiments in a model diffusion cell υinvitro = 19.2 ± 0 .6 µg/cm2/h. The specific transfer rate under these model conditions of glucosamine in a cream of a different composition with a transdermal delivery system lies in the range from 23.5 ± 2.3 to 48.2 ± 1.9 μg/cm2/h. Considering that in real experimental conditions in vivo on rats υ invivo is almost equal to the average value υ invitro determined in a dialysis cell, we can consider our approximate estimate υ = 26.9 μg/cm2/h as a value characterizing the effective penetration of glucosamine from the cream through the skin into the blood plasma.

A comparison of data from the analysis of the pharmacokinetic profiles of glucosamine for human blood plasma, obtained in our work with a single oral dose of 1500 mg, and rat blood plasma with external application of Chondroxide® Maximum cream in our work, indicates the high bioavailability of glucosamine from the drug under study. Pharmacokinetic parameters – AUCt (µg*h/ml) when administered orally to humans is 3.6±0.72, and when the cream is applied externally to a rat is 7.35±1.48; Cmax, µg/ml is 0.49±0.16 (orally for humans) and 7.31±2.08 (topically, Chondroxide® Maximum cream for rats).

The approximately calculated value of β in vivo in humans can be used to estimate the level of glucosamine concentration in the blood plasma of the microvasculature surrounding the joint. For example, according to the instructions for the drug Chondroxide® Maximum in the form of a cream with THC, the amount of cream applied is a strip of cream up to 3 cm long, which approximately corresponds to 3 - 3.5 g. While maintaining the specific amount of cream applied to the skin used in animal experiments in within 4 hours, the area for applying the cream will be 106 cm². The amount of glucosamine delivered into the blood plasma through the capillaries of the papillary dermis will be: (8.1 – 13.5) µg/cm²/hour * 106 cm² * 4 hours = (3434 – 5724) µg.

Assuming the volume of circulating blood in a person is equal to an average of 5500 ml, the most pessimistic (without taking into account the direct penetration of glucosamine in the THC composition through the skin to the synovial membrane) estimate of the average concentration of glucosamine in the blood plasma of the microvasculature surrounding the joint over 4 hours will be value: (3434 – 5724) µg / 5500 ml = (0.62 – 1.04) µg/ml.

When treating osteoarthritis with an injection drug based on glucosamine (LSR-000050 dated December 26, 2007), the course of treatment is 3 intramuscular injections per week, 3 ml each, with a glucosamine content of 400 mg per injection or 0.072 mg/ml blood plasma.

Bioavailability of injectable glucosamine in a large animal model.

According to the authors, the peak concentration (Cmax) of glucosamine in plasma with a single intravenous administration to a healthy horse at the rate of 0.2 mg per 1 ml of blood plasma reached 50 μg/ml, the average concentration of glucosamine in blood plasma over 12 hours was 4.5 µg/ml, and the peak synovial fluid glucosamine concentration was 1.5 µg/ml with a 12-hour mean synovial fluid glucosamine concentration of 0.7 µg/ml.

It should be noted that when glucosamine penetrates from the blood plasma into the synovial fluid, the level of the maximum concentration of glucosamine in the synovial fluid of the inflamed joint, in accordance with the experimental data obtained, can be up to 5 times higher than in the intact joint. The data presented allow us to believe with a high degree of confidence that with osteoarthritis of various stages, the peak concentration of glucosamine in the synovial fluid of the inflamed joint of a horse when administered intravenously can reach a value of 7 - 8 mcg/ml.

Bioavailability of glucosamine by injection in humans.

Considering that the injection of glucosamine to a person is carried out at a concentration 3 times lower than in the model discussed above (0.072 mg per 1 ml of blood plasma), the peak concentration of glucosamine in the blood plasma during a single injection will be approximately 15 - 20 μg/ml, the average concentration in plasma within 12 hours after injection will be about 1.5 - 1.7 μg/ml, and the average concentration of glucosamine in the synovial fluid of a healthy human joint will be 0.25 - 0.3 μg/ml.

Oral bioavailability of glucosamine in humans.

When taken orally, adults with osteoarthritis are prescribed a maximum dose of 1500 mg of glucosamine per day, which is 0.2 mg/ml of blood plasma. Glucosamine is taken orally in the form of capsules or a prepared aqueous solution. The recommended duration of therapy, depending on the severity of the disease, is from 4 to 12 weeks. According to the authors, when 1500 mg of glucosamine is administered to a person once, the peak concentration of glucosamine in the human blood plasma reaches 1.6 μg/ml by 3 hours after administration, the average area under the concentration-time curve over a period of 48 hours is 14.6 μg* hour/ml, then the average concentration from a single dose of glucosamine at a dose of 1500 mg over 48 hours will be 0.3 μg/ml. Accordingly, a dose of 1500 mg taken every day will give an average concentration in human plasma of no more than 0.6 μg/ml. Later work by the same authors shows that when an oral dose of 1500 mg of glucosamine is administered daily for 14 days, glucosamine accumulates in the blood plasma and synovial fluid of a human joint and on the 14th day the average concentration of glucosamine in the blood plasma increases from the endogenous concentration levels are 0.052 µg/ml to 1.28 µg/ml, in the synovial fluid of the joint, respectively from 0.037 µg/ml to 0.78 µg/ml. In other words, the average concentration of glucosamine in the blood plasma after 14 days of administration increases approximately 20 times compared to the endogenous level of glucosamine concentration and 2 times compared to the level of average glucosamine concentration achieved after a single dose. The average concentration of glucosamine in synovial fluid after 14 days of administration also increases approximately 20 times.

Oral bioavailability of glucosamine in a large animal model.

When glucosamine is administered orally to a horse, once, at a dose of 0.2 mg/ml, the peak concentration in blood plasma is 1.13 μg/ml, the average concentration of glucosamine in blood plasma 12 hours after administration is 0.4 μg/ml , the peak concentration of glucosamine in synovial fluid is 0.16 μg/ml, the average concentration of exogenous glucosamine in synovial fluid is 0.072 μg/ml. Taking into account the fact that the specific doses for oral administration to horses and humans in the cases under consideration are equal (0.2 mg/ml), and the parameters of the peak and average concentrations of glucosamine in the blood plasma are very close, it can be assumed that in humans with a single oral administration of glucosamine the average concentration of glucosamine in the synovial fluid will be the same value of 0.07 μg/ml.

Then we can also draw a general conclusion that follows from all the above experimental data on the bioavailability of glucosamine when administered orally to horses and humans. With daily oral administration of glucosamine for 14 days, glucosamine accumulates in the blood plasma and synovial fluid of the inflamed joint; the average concentration of glucosamine, in comparison with the results obtained with a single administration, increases, respectively, by approximately 2 times in the blood plasma in humans from 0.6 μg/ml to 1.28 μg/ml and approximately 11 times in the synovial fluid of an inflamed human joint from 0.07 μg/ml to 0.78 μg/ml.

THE DISCUSSION OF THE RESULTS

Based on research and theoretical calculations, with a single intramuscular injection of glucosamine in a 4% solution of Glucosamine sulfate potassium chloride to a person at a dose of 400 mg (0.072 mg/ml of blood plasma), the peak concentration of glucosamine in plasma can be estimated at 15 - 20 μg/ml , which provides an average level of glucosamine concentration in the synovial fluid during the first 12 hours of 0.25 - 0.3 μg/ml for a healthy joint, and a value of up to 1.25 -1.5 μg/ml for an inflamed joint with a half-life of about 68 hours. With repeated administration 3 times a week, since the next administration occurs after 48 - 72 hours, the concentration of glucosamine in the synovial fluid before each subsequent administration drops to the level of 0.6 - 1.0 μg / ml, and the average concentration of glucosamine in the synovial fluid of the inflamed joint during the course of treatment can be estimated at 1.2 - 1.3 mcg/ml.

Thus, the average concentration of glucosamine in the synovial fluid of the inflamed joint during the injection course of treatment (3 injections per week, IM, 3 ml with a glucosamine content of 400 mg per injection) can be estimated at 1.2 - 1.3 mcg /ml.

When a patient with osteoarthritis takes 1500 mg of glucosamine orally for at least 14 days, daily, in the form of capsules or solution, the average concentration of glucosamine in human blood plasma will reach at least 1.3 μg/ml, the average concentration in the synovial fluid of an inflamed human joint will be not less than 0.7 - 0.8 μg/ml.

Thus, the average concentration of glucosamine in the synovial fluid of an inflamed joint during an oral course of treatment (orally administered at a dose of 1500 mg of glucosamine per day for 14 days) can be estimated at 0.7 - 0.8 μg/ml.

When applying the drug Chondroxide® Maximum, cream with THC once, the average concentration in the blood plasma within 4 hours after each application of THC will be 0.62 - 1.04 mcg/ml.

There are then two ways to evaluate the effectiveness of a standard course of THC treatment. If we take the dependences obtained for oral administration as a basis for the calculation, we obtain the following values. Since the level of the average concentration of glucosamine in the blood plasma after a single application is very close to the values obtained with a single oral administration (0.6 μg / ml), and the frequency of administration is 3 times higher, then with a high degree of probability the mechanism of accumulation of glucosamine in plasma can be applied blood and synovial fluid of the joint. Then, making the assumption that a 3 times greater frequency of administration will lead to a concentration 3 times greater, we conclude that after a course of treatment with Chondroxide® Maximum, cream with THC for 14 days, the average concentration in the blood plasma can be at least 1.8 – 3.1 µg/ml, and in the synovial fluid of an inflamed joint the value is about 0.9 – 1.5 µg/ml or an average of 1.2 µg/ml.

If we take the dependencies obtained for the injection model as a basis for the calculation, we obtain the following values. The average concentration of glucosamine when applying THC is approximately 1.6 times lower than when injecting it, so the average concentration of glucosamine in synovial fluid will be approximately the same times lower and will be 0.17 μg/ml for a healthy joint. Taking into account the information that the level of maximum concentration of glucosamine in the synovial fluid of an inflamed joint is approximately 5 times higher than in an intact joint, the average concentration in the synovial fluid of an inflamed joint can be estimated at 0.8 - 0.9 μg/ml for a patient joint If we take into account that with each application of THC (approximately every 6-8 hours) the concentration of glucosamine in the synovial fluid of the inflamed joint will be restored to the maximum possible level, then we can conclude that the concentration of glucosamine in the synovial fluid of the inflamed joint in this case will be practically maintained at level 0.7 - 0.8 µg/ml or an average of 0.75 µg/ml.

Thus, the average concentration of glucosamine in the synovial fluid of the inflamed joint during the course of treatment with Chondroxide® Maximum, cream with THC (applying the cream 3 times a day in an amount of 3 -3.5 g for 14 days) can be estimated as (0. 7–1.5) µg/ml.

CONCLUSIONS

1. It was experimentally revealed that when the drug Chondroxide® Maximum, cream with glucosamine at a dose of 400 mg/kg, 3 times a day, daily, for a week, was applied to the skin of Sprague-Dawley rats, the amount of glucosamine introduced into the blood plasma using Transdermal Glucosamine Complex amounted to 61.6% of that obtained with a single injection of a 4% solution of Glucosamine sulfate potassium chloride to an animal at a dose of 400 mg/kg.

2. The average value of the specific diffusion of glucosamine when applying the drug Chondroxide® Maximum, cream with Transdermal Glucosamine Complex to the skin of an animal at a dose of 0.033 g/cm² equal to 26.9 µg/cm²/hour is comparable with literature data on the rate of transdermal transfer in in vitro experiments, which ranges from 19.2±0.6 µg/cm²/hour to 48.2±1.9 µg/cm²/hour.

3. A comparative analysis of literary and experimental data, as well as calculations based on them, allowed us to conclude that during treatment in accordance with the instructions for the drug Chondroxide® Maximum, the estimated average concentration of glucosamine in the synovial fluid of an inflamed joint can be (0.7–1 .5) µg/ml, which is 10-75 times higher than the concentration of endogenous glucosamine in the synovial fluid of a human joint (0.02-0.07) µg/ml. This value is comparable to the level achieved by injectable forms of glucosamine and is up to 2 times higher than the level achieved by oral forms of glucosamine.

Relative bioavailability and penetration of glucosamine after topical treatment by Hondroxid® Maximum transdermal glucosamine complex in comparison with oral, injectable routes in experiment on the rats.

Blair Yasso1, Yinghe Li 2, Asafov Alexander3; Melnikova NB4, Muchina IV5

1MB Research Laboratories, 1765 Wentz Road, Spinnerstown, PA 18968, USA, Blair Yasso, BS, Study Director;

2Alliance Pharma, Inc., 17 Lee Blvd, Malvern, PA 19355, USA, Yinghe Li, Bioanalytical Principal Investigator;

3Foura Pacific Pte Ltd, (Singapore), 35 Selegie Road #10-05, Parklane Shopping Mall

Singapore 188307, Asafov Alexander, R&D, CEO;

4 Department of pharmaceutical chemistry of NSMA Russian Ministry of Health (Head of department – Professor, Dr. Melnikova NB, Nizhny Novgorod, Rodionova str, 293)

5Central Research Laboratory of NSMA Russian Ministry of Health (Head of Central Research Laboratory - Professor, Dr. Mukhina IV, Nizhny Novgorod, Gagarin Avenue, 70)

Key words:

relative bioavailability, glucosamine sulfate, transdermal glucosamine complex, micellar transdermal delivery system

SUMMARY

A comparison of the relative bioavailability and intensity of penetration of glucosamine sulfate in oral, injection and topical administration of the dosage form Hondroxide® Maximum as a cream containing micellar system for transdermal delivery of glucosamine in the experiment by Sprague-Dawley rats was carried out. On the base on the pharmacokinetic profiles data of glucosamine in rat blood plasma with daily administration in 3 times a day for 1 week by cream Hondroxide® Maximum 400 mg/kg and the single injection solution of 4% Glucosamine sulfate 400 mg/kg was found that the relative bioavailability was 61.6%. Calculated penetration rate of glucosamine in the plasma through the rats skin in 4 hours, equal to 26.9 μg/cm2 ∙ h, and the penetration of glucosamine through the skin into the plasma after a single dose of cream in 4 hours was 4.12%.

Comparative analysis of literature and experimental data and calculations based on them suggest that medicine Hondroxide® Maximum, cream with transdermal glucosamine complex in the treatment in accordance with the instructions can provide an average concentration of glucosamine in the synovial fluid of an inflamed joint in the range (0.7-1.5) µg/ml, much higher than the concentration of endogenous glucosamine human synovial joint fluid (0.02-0.07 µg/ml).

By theoretical calculations taking into account experimental data it is shown that the medicine Hondroxide® Maximum can reach the bioavailability level of the modern injection forms and exceed the bioavailability level of modern oral forms of glucosamine up to 2 times.

BIBLIOGRAPHY

1. R.D. Altman, Clinical Pharmacology

,
2
(4), 359-371 (2009)

2. M. L. Tiku, H. Narla, M. Jain, P. Yalamanchili, Arthritis Research & Therapy, 9(4), R76, 1-10 (2007).

3. C. Valvason, E. Musacchio, A. Pozzuoli, et al., Rheumatology, 47, 31-35 (2008).

4. V.V. Beregovykh, N.V. Pyatigorskaya, Yu.A. Prudkevich, S.A. Kedik, Bulletin of MITHT,
7
(5), 17-22 (2012).

5. A. Sharma and S. Arora, World Journal of Pharmacy and Pharmaceutical Sciences, 2(6), 6448-6462 (2013).

6. Z. Liang, J. Leslie, A. Adebowale, et al., Journal of Pharmaceutical and Biomedical Analysis, 20(5), 807-814 (1999).

7. Guidelines for conducting preclinical studies of drugs

. Part 1, Grif i K, Moscow (2012).

8. B. Van Ravenzwaay and E. Leibold, Human & Experimental Toxicology, 23, 421-430 (2004).

9. C. G. Jackson, A. H. Plaas, J. D. Sandy, et al., Osteoarthritis and Cartilage, 18, 297-302 (2009).

10. M. Meulyzer, P. Vachon, F. Beaudry, et al, Osteoarthritis Cartilage, 16(9), 973-979 (2008)

11. M. Meulyzer, P. Vachon, F. Beaudry, et al, Osteoarthritis Cartilage, 17(2), 228-34 (2009)

12. S. Persiani E. Roda, L. C. Rovati, et al, Osteoarthritis Cartilage, 13(12), 1041-9 (2005)

13. S. Persiani, R. Rotini, G. Trisolino, et al, Osteoarthritis Cartilage, 15(7), 764-72 (2007)

What foods do they contain?

Before determining what glucosamine and chondroitin are and what they are needed for, let’s find out in which products their highest concentration is found. Substances that have a targeted effect and are directly involved in the restoration, protection and strengthening of articular and cartilage tissues are contained in:

hard cheeses;
beef;
poultry meat;
red fish (mainly salmon).

Properties of drugs containing chondroitin

Chondroitin sulfate will be included in monopreparations and complex supplements. Among the monopreparations there are:

Chondroflex;
Mucosat;
Artron Hondrex;
Artiflex Chondro;
Structum.

Forms of release of medicines containing the active substance:

injection solutions;
capsules;
ointments.

The spectrum of biological effects of chondroitin sulfate can include:

stimulation of the biosynthesis of hyaluronic acid and proteoglycans;
inhibition of degeneration in the cartilage matrix;
correction of manifestations of the inflammatory process in the joint.

Measures to prevent joint diseases

Injuries not only cause unpleasant pain to the victim and take a long time to heal, but also often cause disability. Timely preventive actions will help avoid such problems.

Why, then, are chondroitin and glucosamine needed? Included in foods (mostly of animal origin) and dietary supplements, they have a beneficial effect on ligaments and joints, promoting recovery after stress and preventing them from deteriorating.

Another step is to switch to a proper diet with a balanced menu rich in vitamins, microelements and bioactive nutrients. It is recommended to sharply reduce or completely eliminate the consumption of canned foods, alcoholic and caffeinated drinks, increasing the intake of proteins that strengthen the ligamentous apparatus.

Don't forget about physical exercise. The body needs regular moderate exercise, selected taking into account the body's capabilities.